如题，关于全球医药行业的展望报告，报告数据详实，报告主要内容如下：
Analysis Highlights

• 
  2016 forecasts for the top 50 products have increased by $21.7bn (+13%
  

upgrade) since April 2010;

• 
  Worldwide prescription drug sales total $853bn in 2016; Since April 2010
  

growth revised up from 2.9% to 4.0% (CAGR) over 2010 – 2016;

• 
  Over $255bn of sales at risk from patent expirations in 2011-16;
• 
  Humira world's largest selling product in 2016;
• 
  Pfizer, Novartis and Sanofi competing for top spot in 2016;
• 
  Biotech products fail to overtake small molecule sales within top 100 drugs
  

by 2016;

• 
  Global pharmaceutical R&D spend returns to growth in 2010 following
  

unprecedented decline in 2009; still over investment;

• 
  Pfizer’s 2016 R&D spend revised down by $1.2bn since April 2010;
• 
  Anti-coagulants set to record highest growth of major therapy categories to
  

2016;

• 
  Best year for NME approvals since 2004 as sales potential doubles;
  

number of new drugs approved down 24%;

• 
  GSK falls out of top 5 in 2010; first time since late 1980s;
• 
  Teva continues to dominate generic drug market in 2010;
• 
  Roche’s company value slumps in 2010 due to setbacks to Avastin and
  

taspoglutide;

• 
  Novo Nordisk’s share price soars in 2010 following series of positive
  

events within anti-diabetic business

部分图标目录如下